Examining the influence of PTH(1-34) on tissue strength and composition.

Gardinier JD, Al-Omaishi S, Rostami N, Morris MD, Kohn DH

Bone24 Sept 2018Cited by 21 (Europe PMC)

PMID30261327PMCIDPMC6202137DOI10.1016/j.bone.2018.09.019PepBankPUB-30261327

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In adult male mice, PTH(1-34) decreased the carbonate-to-phosphate ratio across the entire tissue.
In plain wordsIn mice, PTH(1-34) decreased the tissue carbonate-to-phosphate ratio compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCarbonate-to-phosphate ratio
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
In response to PTH(1-34), Raman spectroscopy revealed a significant decrease in the carbonate-to-phosphate ratio and crystallinity across the entire tissue, while the mineral-to-matrix ratio demonstrated a significant decrease in just the perilacunar region.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132701
02AnimalAnimal study (in vivo)Mechanism
In adult male mice, PTH(1-34) decreased crystallinity across the entire tissue.
In plain wordsIn mice, PTH(1-34) decreased tissue crystallinity compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCrystallinity
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
In response to PTH(1-34), Raman spectroscopy revealed a significant decrease in the carbonate-to-phosphate ratio and crystallinity across the entire tissue, while the mineral-to-matrix ratio demonstrated a significant decrease in just the perilacunar region.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132702
03AnimalAnimal study (in vivo)Mechanism
In adult male mice, PTH(1-34) decreased the mineral-to-matrix ratio only in the perilacunar region.
In plain wordsIn mice, PTH(1-34) decreased the mineral-to-matrix ratio near bone cell spaces compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePerilacunar mineral-to-matrix ratio
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
In response to PTH(1-34), Raman spectroscopy revealed a significant decrease in the carbonate-to-phosphate ratio and crystallinity across the entire tissue, while the mineral-to-matrix ratio demonstrated a significant decrease in just the perilacunar region.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132703
04AnimalAnimal study (in vivo)Mechanism
In adult male mice, altered perilacunar composition largely explained increased tissue strength after PTH(1-34).
In plain wordsIn mice, changes near bone cell spaces largely explained increased tissue strength after PTH(1-34).
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTissue strength
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
The shift in perilacunar composition largely explained the corresponding increase in tissue strength, while the degree of new tissue added at the endosteum and periosteum did not produce any significant changes in cortical area or moment of inertia that would explain the increase in tissue strength.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132704
05AnimalAnimal study (in vivo)Mechanism
In adult male mice, new tissue after PTH(1-34) did not significantly change cortical area to explain increased strength.
In plain wordsIn mice, new tissue after PTH(1-34) did not significantly change cortical area to explain increased strength.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical area
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
The shift in perilacunar composition largely explained the corresponding increase in tissue strength, while the degree of new tissue added at the endosteum and periosteum did not produce any significant changes in cortical area or moment of inertia that would explain the increase in tissue strength.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132705
06AnimalAnimal study (in vivo)Mechanism
In adult male mice, new tissue after PTH(1-34) did not significantly change moment of inertia to explain increased strength.
In plain wordsIn mice, new tissue after PTH(1-34) did not significantly change moment of inertia to explain increased strength.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMoment of inertia
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
The shift in perilacunar composition largely explained the corresponding increase in tissue strength, while the degree of new tissue added at the endosteum and periosteum did not produce any significant changes in cortical area or moment of inertia that would explain the increase in tissue strength.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132706
07AnimalAnimal study (in vivo)Mechanism
In adult male mice, PTH(1-34) increased resistance to crack formation in existing tissue.
In plain wordsIn mice, PTH(1-34) increased resistance to cracks in existing bone tissue compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseResistance to crack formation
Study
C57BL/6J micen: not reported in source
Adult male mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 weeksAs given in this study (C57BL/6J mice).
Source sentences
Summary
Furthermore, fatigue testing revealed a greater resistance to crack formation within the existing tissue following PTH(1-34) treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male C57BL/6J mice were treated daily with PTH(1-34) or vehicle for 3 weeks.
Report a problemFND-3026132707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.